FDA Approves Fast-Acting Fiasp Insulin
Insulin Nation
SEPTEMBER 29, 2017
Novo Nordisk announced on September 29th, 2017 that it has received FDA market approval for its new fast-acting insulin, Fiasp*. This was the second attempt by Novo Nordisk to gain the FDA’s approval for the long-anticipated fast-acting insulin. The drug already has been on the market in Europe, Canada, and Germany.
62 
Let's personalize your content